Transcode Therapeutics holders report 4.9% RNAZ stake
Transcode Therapeutics, Inc. shareholders Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz filed an amended Schedule 13G indicating a passive ownership position in the company’s common stock.
Rhea-AI Filing Summary
Transcode Therapeutics, Inc. shareholders Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz filed an amended Schedule 13G indicating a passive ownership position in the company’s common stock. As of the event date of 12/31/2025, each reporting person beneficially owns 41,601 shares, representing 4.9% of the outstanding common stock.
The filing states that the reporting persons have no sole voting or dispositive power over the shares but share voting and dispositive power for all 41,601 shares. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Transcode Therapeutics, but rather as a passive investment.
Positive
- None.
Negative
- None.
FAQ
What stake in Transcode Therapeutics (RNAZ) is reported in this Schedule 13G/A?
Who are the reporting persons in this Transcode Therapeutics (RNAZ) Schedule 13G/A?
What percentage of Transcode Therapeutics (RNAZ) does each reporting person beneficially own?
What is the event date for the ownership reported for Transcode Therapeutics (RNAZ)?
Is the Transcode Therapeutics (RNAZ) stake reported as a passive investment?
What class of Transcode Therapeutics (RNAZ) securities is covered by this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.